Nitric Oxide Administration Using an Oxygen Hood: A Pilot Trial

Background

We have shown earlier that inhaled nitric oxide (iNO) administered by oxygen hood reduces pulmonary hypertension in an animal model (J Perinatol 2002; 22:50-6). Our objective in this study was to determine feasibility of iNO by oxygen hood in neonates with elevated alveolar-arterial oxygen gradients (A-aDO₂).

Methods/Principal Findings

Masked randomized controlled pilot trial. Inclusion criteria were: gestation≥34 weeks, age<7 days, with post-ductal arterial line, and A-aDO₂ 400–600. Infants were randomized to study gas (iNO 20 ppm or equivalent O₂ flow) for 1 hr which was then weaned over the next 4 hours. Primary outcome was PaO₂ one hour post-randomization. Four infants each were randomized to iNO or O₂ (controls). Two of the four infants given iNO had an increase in PaO₂ of >100 torr, while oxygenation was unchanged in the controls. Methemoglobinemia and other adverse effects were not noted in any infant. Environmental levels of NO and NO₂ were minimal (<1 ppm) at >0.3 m from the hood.

Conclusions

Administration of iNO by oxygen hood is feasible. Larger randomized controlled trials are required to measure the efficacy and determine an appropriate target population for this technique.

Trial Registration

ClinicalTrials.gov {"type":"clinical-trial","attrs":{"text":"NCT00041548","term_id":"NCT00041548"}}NCT00041548